Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-08-26Clinical Trial Update: Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
The clinical trial assessing precision performance status in breast cancer patients receiving neoadjuvant chemotherapy has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC [Phase 1]
Pfizer's Phase 1 trial of a vaccine-based immunotherapy regimen for non-small cell lung cancer and triple-negative breast cancer was termina…
-
CLINICAL_TRIALS research · 2024-08-23Clinical Trial Update: CTS2190 Phase I /II Clinical Study in Patients [Phase 1, Phase 2]
CTS2190 is a Phase 1/2 clinical study by CytosinLab Therapeutics evaluating CTS2190 in solid tumors, including pancreatic cancer, non-small …
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors [Phase 1, Phase 2]
Cantargia AB's CAN04 first-in-human study in solid malignant tumors (Phase 1/2) has completed. The trial encompassed several indications, in…
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity
A completed clinical trial investigating molecular subtypes of triple-negative breast cancer and potential immunogenic differences related t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-08-21Clinical Trial Update: A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer [Phase 3]
Phase 3 trial comparing atezolizumab plus adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in operable triple-nega…
-
CLINICAL_TRIALS trial_result · 2024-08-20Clinical Trial Update: Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating pembrolizumab in combination with binimetinib in locally advanced or metastatic triple-negative breast c…
-
CLINICAL_TRIALS research · 2024-08-20Clinical Trial Update: Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer
This clinical trial update reports on PD-L1 expression in HER2-positive breast cancer and triple-negative breast cancer. The study is active…
-
CLINICAL_TRIALS other · 2024-08-20Clinical Trial Update: A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer [Phase 1, Phase 2]
This entry describes a Phase I/II clinical trial of UCB4594 for multiple advanced solid tumors, including head and neck squamous cell carcin…
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) [Phase 2]
Phase 2 study MK-2140-002 evaluating Zilovertamab vedotin (VLS-101) in solid tumors including triple-negative breast cancer and non-small-ce…
-
CLINICAL_TRIALS trial_result · 2024-08-09Clinical Trial Update: CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating the combination of CFI-400945 and Durvalumab in advanced triple-negative breast cancer; results were poste…
-
CLINICAL_TRIALS trial_result · 2024-08-09Clinical Trial Update: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. [Phase 1, Phase 2]
A Phase 1/2 trial of ImmunityBio's NANT TNBC vaccine (QUILT-3.067) for triple-negative breast cancer that progressed after standard therapy …
-
CLINICAL_TRIALS research · 2024-08-02Clinical Trial Update: LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating LM-108 in combination with a PD-1–based therapy for patients with recurrent or metastatic triple-nega…
-
CLINICAL_TRIALS research · 2024-08-02Clinical Trial Update: Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study [Phase 2]
Open-phase 2 multicenter trial evaluating Milaberon in advanced solid tumors across multiple indications, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) [Phase 3]
Phase 3 trial evaluating trilaciclib in combination with gemcitabine and carboplatin for metastatic triple-negative breast cancer has comple…
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss [Phase 3]
A Phase 3 study evaluating alpelisib with nab-paclitaxel in advanced triple-negative breast cancer with PIK3CA mutation or PTEN loss was ter…
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors [Phase 2]
A Phase 2 trial evaluating Cediranib in combination with Olaparib in advanced solid tumors has posted results as of 2024-07-30. Indications …
-
CLINICAL_TRIALS trial_result · 2024-07-26Clinical Trial Update: Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating ipatasertib in combination with non-taxane chemotherapy for advanced or metastatic triple-negative breast cancer …
-
CLINICAL_TRIALS research · 2024-07-22Clinical Trial Update: A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer [Phase 1, Phase 2]
A Phase 1/2 trial evaluating safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early re…
-
CLINICAL_TRIALS research · 2024-07-18Clinical Trial Update: A Phase II Study of Triple-negative Breast Cancer Brain Metastases. [Phase 2]
A Phase II clinical trial evaluating treatment for brain metastases in patients with triple-negative breast cancer, currently recruiting.
-
CLINICAL_TRIALS research · 2024-07-11Clinical Trial Update: Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment [NA]
This clinical trial update describes an exercise intervention for women with triple-negative breast cancer undergoing oncologic treatment; t…
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating Imprime PGG in combination with pembrolizumab in advanced melanoma and triple-negative breast cancer has completed,…
-
CLINICAL_TRIALS research · 2024-07-08Clinical Trial Update: Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating dasatinib in combination with quercetin to overcome chemotherapy resistance in triple-negative breast…
-
CLINICAL_TRIALS research · 2024-07-08Clinical Trial Update: Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) [Phase 2]
This is a Phase 2 clinical trial evaluating short-term pre-operative durvalumab (MEDI-4736) in patients with early-stage small triple-negati…
-
CLINICAL_TRIALS trial_result · 2024-07-05Clinical Trial Update: A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) [Phase 1]
This update reports the completion of a Phase 1 study (DUET-3) evaluating XmAb23104 in patients with selected advanced solid tumors.